R&D Partner Content 13th HPAPI: Process Development for Highly Potent Drugs The rise in novel, more potent compounds, alongside EU Annex 1, are mounting pressure on biopharma, CDMOs and equipment providers to evolve their industrial hygiene, process engineering and
Partner Content Partner Content 11th Annual Pharmaceutical Microbiology Europe Conference Sponsored by: Microgenetics Co-chairs Di Morris, Clinical Auditor, AstraZeneca and Nigel Cryer, Deputy Director Global Audit, Sanofi
Events Partner Content 2nd Annual Next Generation Pharmaceutical Cleanrooms Confere... Next Gen Pharma Cleanrooms
Events Partner Content 2nd Annual Aseptic Processing Conference 2nd Annual Aseptic Processing Conference
Events Partner Content SMi’s 5th Annual Pharmaceutical Microbiology East Coast Conf... Pharmaceutical Microbiology East Coast
News FDA clears AZ's Imfinzi for aggressive lung cancer AstraZeneca's Imfinzi becomes the first cancer immunotherapy to be FDA-approved for limited-stage small cell lung cancer (LS-SCLC).
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.